Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus

INTRODUCTION/OBJECTIVES: The ASCORE study on treatment for rheumatoid arthritis (RA) showed better retention and clinical response rates for abatacept as first-line versus later-line therapy. This post hoc analysis of ASCORE assessed 2-year retention, efficacy, and safety of subcutaneous (SC) abatac...

Descripción completa

Detalles Bibliográficos
Autores principales: Alten, Rieke, Tony, Hans-Peter, Bannert, Bettina, Nüßlein, Hubert, Rauch, Christiane, Connolly, Sean E., Chartier, Melanie, Lozenski, Karissa, Hackl, Roland, Forster, Adrian, Peichl, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412468/
https://www.ncbi.nlm.nih.gov/pubmed/37314665
http://dx.doi.org/10.1007/s10067-023-06649-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412468/
https://www.ncbi.nlm.nih.gov/pubmed/37314665
http://dx.doi.org/10.1007/s10067-023-06649-x

Ejemplares similares